SUMMARY
# Experiment: Autoimmune Hypothesis Testing in AD
## Background and Rationale
The autoimmune hypothesis in Alzheimer's disease represents a paradigm-shifting approach to understanding the heterogeneous nature of neurodegeneration, proposing that a substantial subset of Alzheimer's patients develops the disease through mechanisms fundamentally different from the canonical amyloid cascade hypothesis. This comprehensive clinical investigation addresses the growing recognition that Alzheimer's disea
METHODOLOGY NOTES
**Phase 1: Patient Recruitment and Stratification (Months 1-6)**
• Recruit 300 Alzheimer's disease patients (mild-moderate stages, CDR 0.5-2.0) from memory clinics
• Recruit 150 age-matched cognitively normal controls
• Obtain comprehensive medical history, neuropsychological assessments (MMSE, MoCA, ADAS-Cog)
• Collect demographic data, medication history, and comorbidity profiles
• Perform MRI brain imaging for volumetric analysis and exclude other pathologies
**Phase 2: Comprehensive Biomarker Screening (Months 4-8)**
• Collect fasting blood samples (20mL) and CSF samples (15mL) from all participants
• Screen for neural autoantibodies using multiplex immunoassay panel: anti-NMDAR, anti-AMPAR, anti-GABA-B, anti-LGI1, anti-CASPR2, anti-contactin-associated protein, anti-GAD65, anti-MOG, and anti-aquaporin-4
• Measure inflammatory biomarkers: TNF-α, IL-1β, IL-6, IL-17, IFN-γ, and complement components C3a, C5a
• Assess T-cell populations using flow cytometry: CD4+/CD8+ ratios, regulat